Healthcare policy by other means: Cancer clinical research as “oncopolicy”

Cambrosio, Alberto; Campbell, Jonah; Keating, Peter; Polk, Jessica Beth; Aguilar‐Mahecha, Adriana; Basik, Mark

doi:10.1016/j.socscimed.2021.114576

Cited by 2 publications

(2 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Challenges of PCM are also particularly relevant for HTA, especially concerning agnostic indications. These trials have been termed 'histology-inclusive' , as they maintain the tissueagnostic orientation of precision oncology, without losing the relevance of histologic categorisation [22]. DLCTs have an additional cutting-edge feature: stage III constitutes a pay-forperformance model: after the first 4 months of treatment, supplied by the pharmaceutical companies, drugs are covered, only if clinical benefit is confirmed.…”

Section: Discussionmentioning

confidence: 99%

“…DLCTs have an additional cutting-edge feature: stage III constitutes a pay-forperformance model: after the first 4 months of treatment, supplied by the pharmaceutical companies, drugs are covered, only if clinical benefit is confirmed. This constitutes an 'implementation device' for PCM and aims to expand access to drugs besides generating clinical evidence; such an approach also allows for reframing of healthcare as a 'learning system' , recentred on research and simultaneously providing inputs to implementation of healthcare policies in PCM [22].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Pioneering the implementation of a precision oncology strategy in Portugal: the Precision Oncology Platform trial

Mainoli,

Assis,

Dinis

et al. 2024

View full text Add to dashboard Cite

Background and purpose: The Precision Oncology Platform (POP) trial represents the effort of the Portuguese Oncology Institute of Porto (IPO Porto) for joining other leading European institutions in both ‘Personalised Cancer Medicine for all EU citizens’ (PCM4EU), and ‘PRecisIon Cancer MEdicine RepurpOsing SystEm Using Pragmatic Clinical Trials’ (PRIME-ROSE) consortia, enabling the development of the Portuguese version of the Drug Rediscovery Protocol (DRUP)-like Clinical Trial (DLCT), based on the experience of the DRUP trial developed in The Netherlands. Patients/material and methods: The POP trial is a phase II, pragmatic multicentric, non-randomised, open-label study, designed entirely like the other DLCTs. Its primary objective is to describe anti-tumour activity of targeted anticancer drugs in patients with advanced malignancies harbouring actionable molecular alterations. The primary endpoint is disease control rate (DCR). Secondary endpoints encompass treatment-related grade ≥3 adverse events, objective response rate (ORR), duration of response (DOR), progression-free survival (PFS), and overall survival (OS). Exploratory objectives will assess biomarkers, resource use and costs, and patient-reported outcome measures (PROMs). Interpretation: The POP trial will offer access to innovative treatments for patients without further therapeutic options and provide evidence on efficacy and safety of molecularly-guided treatments. Methodologically, it represents a pioneer approach in Portugal, including a pay-for-performance model embedded in the clinical trial. The POP trial represents a unique opportunity to integrate clinical research within cancer care, pursuing an evidence-based precision oncology strategy, and facilitating its rational and cost-effective implementation into the Portuguese healthcare system.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%